title: Systemic and local interferon gamma gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice.
abstract: Allergen-induced airway hyperresponsiveness, an animal model of asthma in humans, may respond to immunotherapy with Th1 cytokines. For example, local administration of recombinant IL-12 or IFN-gamma, or intratracheal delivery of the genes for these cytokines, has been shown to reduce the severity of allergen-induced airway hyperresponsiveness (AHR) in rodent models. We reasoned that systemic cytokine gene delivery to the lungs by intravenous injection of lipid-DNA complexes might also be an effective approach to treatment of allergen-induced AHR. Therefore, the effects of either systemic or local pulmonary IFN-gamma gene delivery were evaluated in mice with allergen-induced AHR. The effects of treatment on AHR, airway eosinophilia and cytokine production, and serum IgE concentrations were evaluated in mice that were first sensitized to ovalbumin and then subjected to aerosol ovalbumin challenge. Intravenous IFN-gamma gene delivery significantly inhibited development of AHR and airway eosinophilia and decreased serum IgE levels, compared with control mice or mice treated with noncoding DNA. Intratracheal IFN-gamma gene delivery also significantly inhibited AHR and airway eosinophilia, but did not affect serum IgE levels. Treatment with recombinant IFN-gamma was much less effective than IFN-gamma gene delivery by either route. We conclude that either systemic or local pulmonary delivery of a Th1 cytokine gene such as IFN-gamma may be an effective approach for treatment of allergen-induced asthma.
authors.affiliation: Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206, USA.
authors.forename: S W
authors.initials: SW
authors.lastname: Dow
authors.forename: J
authors.initials: J
authors.lastname: Schwarze
authors.forename: T D
authors.initials: TD
authors.lastname: Heath
authors.forename: T A
authors.initials: TA
authors.lastname: Potter
authors.forename: E W
authors.initials: EW
authors.lastname: Gelfand
mesh_terms: D000485:Allergens / Q000009:adverse effects*; D000818:Animals; D001249:Asthma / Q000139:chemically induced / Q000628:therapy; D016535:Bronchial Hyperreactivity / Q000139:chemically induced / Q000628:therapy*; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D004802:Eosinophilia; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D007073:Immunoglobulin E / Q000097:blood; D007371:Interferon-gamma / Q000008:administration & dosage / Q000235:genetics*; D008081:Liposomes / Q000008:administration & dosage; D008168:Lung / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D014132:Trachea
chemical_list: D000485:Allergens; D016207:Cytokines; D008081:Liposomes; D007073:Immunoglobulin E; D007371:Interferon-gamma; D010047:Ovalbumin